About the Editor

Dr. Albensi completed his PhD in Neuroscience at the University of Utah’s School of Medicine in 1995. He obtained advanced training as a Postdoctoral Fellow at the Georgetown Institute of Cognitive and Computational Sciences (GICCS) at Georgetown University Medical Center where he worked with a high field MRI system for assessing brain trauma and its effect on hippocampal structure and physiology. Thereafter he trained under Dr. Mark Mattson as a Postdoctoral Scholar at the Sanders-Brown Center on Aging at the University of Kentucky’s Medical School and studied the involvement of NF-kB in synaptic plasticity. Subsequently, he participated in clinical trials research at Pfizer, Inc. in Ann Arbor, Michigan. Currently he holds the Honourable Douglas Everett, Patricia Everett and the Royal Canadian Properties Endowment Fund Chair and is an Associate Professor of Pharmacology and Therapeutics at the University of Manitoba, Winnipeg, Canada. In addition, he is an Adjunct Professor of Electrical and Computer Engineering at this same school and a Principal Investigator in the Division of Neurodegenerative Disorders at the St. Boniface Research Centre. He is also a Research Affiliate for the University of Manitoba’s Centre on Aging and a Scientist at the Manitoba Institute for Child Health (MICH). He has published more than 100 articles that include peer-reviewed experimental papers, invited book chapters and reviews, abstracts, and other CNS relevant manuscripts on synaptic plasticity, memory, and neuronal excitability. In addition he has been a member of several grant review panels around the world, including the NIH, CIHR, Alzheimer’s Society of Canada, Alzheimer’s Association (USA), Wellcome Trust, American Institute of Biological Sciences, and the U.S. Civilian Research & Development Foundation. He is also on the editorial board of CNS and Neurological Disorders - Drug Targets. He is married and lives in Winnipeg, Canada with his four daughters.